Luteolin in the Management of Type 2 Diabetes Mellitus

Luteolin in the Management of Type 2 Diabetes Mellitus R. Sangeetha Department of Biochemistry, School of Life Sciences, Vels Institute of Science, Technology and Advanced Studies, Chennai - 600 117, Tamil Nadu, India https://orcid.org/0000-0002-5299-0224

Diabetes is an increasing pandemic and several million people are affectedbythis disease worldwide. The treatment of diabetes includes lifestyle modifications, oral antidiabetic drugs and insulin. The chronic use of oral antidiabetic drugs produces undesirable side effects. Hence safe alternative medicines are always sought after. Plant phytochemicals are the best alternatives as they possess a wide spectrum of pharmacological activities. Flavonoids are an important class of phytocomponent which is commonly present in fruits and vegetables. Luteolin belongs toflavone class of flavonoid which has multiple health benefitslike antioxidant, antidiabetic,anti-inflammatory and anti-cancer properties. Luteolin mediates several pharmacological actions of which the role of luteolin in the treatment of diabetes is well studied. In thisreview, the use of flavonoids as antidiabetic agents is discussed, with special reference to luteolin.Luteolin mediates its anti-diabetic potential by maintaining blood glucose levels and improving the sensitivity of body cells to insulin and these mode of actions have been discussed here.
6 12 2019 8 31 2019 393 398 http://creativecommons.org/licenses/by/4.0/ 10.12944/CRNFSJ.7.2.09 http://www.foodandnutritionjournal.org/volume7number2/luteolin-in-the-management-of-type-2-diabetes-mellitus/ https://app.ithenticate.com/en_us/report/46634271/similarity 10.2337/diaclin.28.2.53 Ahmad L. A., Crandall J. P. Type 2 Diabetes Prevention: A Review. Clin Diab. 2010;28(2):53-54. CrossRef 10.5001/omj.2012.68 Olokoba A. B., Obateru O. A., Olokoba L. B. Type 2 Diabetes Mellitus: A Review of Current Trends. Oman Med J. 2012;27(4):269-273. CrossRef 10.1155/2015/685248 Yang W. C., Chang C. L. T., Li C. R., Nammi A., Cho W. C. S. Complementary and Alternative Medicine for Diabetes 2014. Evid Based Complement Alternat Med. 2015;2015:Article ID 685248. CrossRef 10.3389/fendo.2017.00006 Chaudhury A., Duvoor C., Dendi V.S.R., Kraleti S., Chada A., Ravilla R., Marco A., Shekhawat N.S., Montales M.T., Kuriakose K., Sasapu A., Beebe A., Patil N., Musham C.K., Lohani G.P., Mirza W. Clinical Review of Antidiabetic drugs: Implications for Type 2 diabetes mellitus management. Front Endocrinol. 2017; 8:6 CrossRef 10.1186/s12986-015-0057-7 Vinayagam R., Xu B. Antidiabetic properties of dietary flavonoids: a cellular mechanism review. Nutr Metab. 2015; 12:60. CrossRef 10.1016/s2221-6189(13)60126-2 Arumugam G., Manjula P., Paari N. A review: Anti diabetic medicinal plants used for diabetes meelitus. J Acute Dis. 2013;196-200. CrossRef 10.1155/2013/712092 Rizvi S. I, Mishra N. Traditional Indian medicines used for the management of diabetes mellitus. J Diab. Res. 2013;2013:Article ID 712902. CrossRef 10.1016/s2221-1691(12)60032-x Patel D. K, Prasad S. K, Kumar R., Hemalatha S. An overview of antidiabetic medicinal plants having insulin mimetic property. Asian Pac J Trop Biomed. 2012;2(4):320-330. CrossRef 10.4314/tjpr.v7i3.14693 Tapas A. R, Sakarkar D. M, Kakde R. B.Flavonoids as Nutraceuticals: A Review. Trop J Pharm Res. 2008;7(3):1089-1099. CrossRef 10.1017/jns.2016.41 Panche A. N, Diwan A. D, Chandra S. R. Flavonoids: an overview. J Nutl Sci. 2016;5(47):1-15. CrossRef 10.1093/ajcn/79.5.727 Manach C., Scalbert A., Morand C., Remesy C., Jimenez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004;79:727– CrossRef Iwashina T. Flavonoid properties of five families newly incorporated into the order Caryophyllales (Review). Bull Nat Mus Nat Sci. 2013;39:25– 10.1017/s0954422418000082 Gentile D., Fornai M., Pellegrini C., Colucci R., Blandizzi C., Antonioli L. Dietary flavonoids as a potential intervention to improve redox balance in obesity and related comorbidities: a review. Res. Rev. 2018; 31(2):239-247 CrossRef 10.2174/156800908786241050 Lin Y.,Shi R., Wang X.,Shen H. M.Luteolin, a flavonoid with potentials for cancer prevention and therapy. Curr Cancer Drug Targets. 2008;8(7): 634–646. CrossRef 10.1016/s0014-5793(98)01304-0 Shimoi K., Okada H., Furugori M., Goda T., Takase S., Suzuki M., Hara Y., Yamoto H., Kinae H. Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. FEBS Lett. 1998;438:220–224. CrossRef 10.1016/S0035-3787(07)90475-0 Stadelmann C. Recent advances in the neuropathology of multiple sclerosis. JNeurochem. 2007;163: 657-61. CrossRef 10.1155/2011/323171 Wang G. G., Lu X. H., Li W., Zhao X., Zhang C. Protec­tive Effects of Luteolin on Diabetic Nephropa­thy in STZ-Induced Diabetic Rats. Evid Based Complement Alternat Med. 2011; 2011:323171. CrossRef Zhang Y., Xiao-Qin Tian., Xiang-Xin Song., Jia-Pu Ge., Yan-Cheng Xu. Luteolin protect against diabetic cardiomyopathy in rat model via regulating the AKT/GSK-3β signalling pathway. Biomed Res. 2017; 28 (3):1359-1363 10.1016/j.biopha.2010.02.001 Pari L., Srinivasan S. Antihyperglycemic effect of diosmin on hepatic key enzymes of carbohydrate metabolism in streptozotocin-nicotinamide induced diabetic rats. Biomed Pharmacother. 2016;64:477–4 CrossRef 10.1016/j.cbi.2014.05.003 Sendrayaperumal V., Iyyam Pillai S., Subramanian S. Design, synthesis and characterization of zinc-morin, a metal flavonol complex and evaluation of its antidiabetic potential in HFD-STZ induced type 2 diabetes in rats. Chem-Biol Interact. 2014;219:9– CrossRef 10.4103/0973-1296.149708 Eid H. M, Nachar A., Thong F., Sweeney G., Haddad P. S. The molecular basis of the antidiabetic action of quercetin in cultured skeletal muscle cells and hepatocytes. Pharmacogn Mag. 2015;11:74– CrossRef 10.1016/j.ejphar.2011.07.021 Prasath G. S., Subramanian S. P. Modulatory effects of fisetin, a bioflavonoid, on hyperglycemia by attenuating the key enzymes of carbohydrate metabolism in hepatic and renal tissues in streptozotocin-induced diabetic rats. Eur J Pharmacol.; 2011; 668:492–49 CrossRef 10.1016/j.jnutbio.2009.06.012 Cho K. W., Lee O. H., Banz W. J., Moustaid-Moussa N., Shay N. F., Kim Y. C. Daidzein and the daidzein metabolite, equol, enhance adipocyte differentiation and PPAR γ transcriptional activity. J Nutr Biochem. 2010;21:841–847 CrossRef 10.3177/jnsv.52.149 Tadera K., Minami Y., Takamatsu K., Matsuoka T. Inhibition of glucosidase and amylase by flavonoids. J Nutrl Sci Vitaminol. 2006;52: 149-153. CrossRef 10.1016/j.nut.2011.01.008 Pereira D. F., Cazarolli L. H., Lavado C., Mengatto V., Guedes M. S. R. B. F. A., Pizzolatti M. G, Silva F. R. M. B. Effects of flavonoids on a-glucosidase activity: Potential targets for glucose homeostasis. Nutrition 2011;27:1161–1167. CrossRef 10.1016/j.jtusci.2015.09.006 Ghamali, Chtita S., Hmamouchi R., Adad A., Bouachrine M., Lakhlifi T. The inhibitory activity of aldose reductase of flavonoid compounds: Combining DFT and QSAR calculations. J Taibah Unv Sci. 2016;10: 534–542 CrossRef 10.1080/09168451.2015.1116928 Zang Y., Igarashi K., Li Y. Anti-diabetic effects of luteolin and luteolin-7-O-glucoside on KK-Ay BiosciBiotechnol Biochem. 2016; 80(8):1580-1586. CrossRef Li M., Li Q., Zhao Q., Zhang J., Lin J. Luteolin improves the impaired nerve functions in diabetic neuropathy: behavioral and biochemical evidences. Int J Clin Expt Pathol. 2015;8(9):10112-10120 10.3389/fphar.2017.00692 Luo Y., Shang P., Li D. Luteolin: A Flavonoid that Has Multiple Cardio-Protective Effects and Its Molecular Mechanisms. Front Pharmacol. 2017; 8: Article 692 CrossRef 10.4172/2324-8602.1000207 Mirhafez S. R., Avan A., Darsouie R., Heidari-Bakavoli A., Parizadeh S. M. R., Mazidi M., Savadi H., Ibrahimi M., Ferns G. A, Mobarhan M. G. Increased pro-Oxidant–Antioxidant Balance in Patients with Diabetes Mellitus. Int J Cardiovasc Res.2015; 4:3 CrossRef 10.1016/j.jnutbio.2013.06.003 Babu V. A., Liu D., Gilbert E. R.Recent advances in understanding the anti-diabetic actions of dietary flavonoids. J Nutr Biochem. 2013; 24(11): 1777-1789. CrossRef 10.2147/dmso.s48260 Mackenzie W. A.,Elliott B. Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2014; 7: 55–64. CrossRef 10.1039/c4ra10756j Lu H., Chen Y., Sun X. B., Tong B., Fan X. H. Effects of luteolin on retinal oxidative stress and inflammation in diabetes. RSC Adv. 2015;5:4898-4904. CrossRef 10.4162/nrp.2017.11.5.430 Kim A., Lee W., Yun J. Luteolin and fisetin suppress oxidative stress by modulating sirtuins and forkhead box O3a expression under in vitro diabetic conditions. Nutr Res Prac. 2017; 11(5): 430-434. CrossRef 10.1093/bfgp/ely036 Ambasta R. K., Gupta R., Kumar D., Bhattacharya S., Sarkar A., Kumar P. Can luteolin be a therapeutic molecule for both colon and cancer and diabetes? Briefings in Functional Genomics. 2018; ely036. CrossRef 10.3389/fphar.2018.01094 Gentile D., Fornai M., Pellegrini C., Colucci R., Benvenuti L., Duranti E., Masi S., Carpi S., Nieri P., Nericcio A., Garelli F., Virdis A., Pistelli L., Blandizzi C., Antonioli L. Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity. Front. Pharmacol. 2018; 9:1094